Xeris Biopharma: files patent infringement lawsuits

What happened Xeris Biopharma Holdings, Inc. filed patent infringement lawsuits in the United States District Court for the District of New Jersey through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., on Oct 14, 2026, following the grant of U.S. Patent No. 12,758,502 related to the company’s KEVEYIS® (dichlorphenamide) product.
The complaints allege that the defendants will infringe the ’502 patent by making, using, selling, offering for sale, and/or importing their generic dichlorphenamide products and seek a judgment of infringement, injunctive relief, monetary damages adequate to compensate for the infringement, enhanced damages where permitted by law, attorneys’ fees, costs, and such other relief as the court deems appropriate.

Key details

• Lawsuits filed in the United States District Court for the District of New Jersey; filed Oct 14, 2026.
• Patent at issue: U.S. Patent No. 12,758,502 (the “’502 patent”) for KEVEYIS® (dichlorphenamide).
• Defendants in two separate actions: (i) Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, and Lemed Specialty Pharmacy Arizona, LLC; and (ii) Rising Pharma Holdings, Inc. and Rising Pharma Specialties Pvt. Ltd.
• Relief sought: judgment of infringement, injunctive relief, monetary damages, enhanced damages where permitted, attorneys’ fees, costs, and other relief.

Why it may matter The company reported this under Item 8.01 (Other events), which covers other material events the company chose to disclose. A filing does not show why the insider traded or why the company acted.